Nephros (NEPH) Stock
Specialized filtration developer for medical and water markets. Here's the price, business snapshot, and what's worth knowing about Nephros in July 2026.
Nephros Inc (NEPH) is a small-cap company operating in the medical technology and filtration space. It develops specialised filtration products used in clinical settings and water purification applications; these products are aimed at reducing contaminants and improving fluid quality for healthcare and industrial customers. With a market capitalisation of about $51.41 million, Nephros is a relatively small issuer and can be subject to greater share-price volatility and liquidity constraints than larger peers. Key points for investors to consider include the company’s product adoption in target markets, regulatory approvals, reimbursement dynamics, and the competitive landscape for medical and water filtration technologies. Financial transparency, cash runway and management execution are also central for smaller companies. This summary is for educational purposes only and is not personal financial advice; investors should do their own research, check the company’s filings and consider their risk tolerance before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Nephros Inc. stock with a target price of $4.75, indicating potential growth.
Financial Health
Nephros Inc. is generating solid revenue and cash flow, indicating a stable financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NEPH
Rare Kidney Disease Treatments | A Market Overview
The FDA's expanded approval of Travere's FILSPARI validates the growing market for rare nephrology treatments. This milestone creates positive momentum for biopharma companies developing innovative therapies for underserved kidney conditions.
Published: 14 April 2026
Explore BasketRenal Therapy Stocks (Biopharma & Research) In Focus
Vertex Pharmaceuticals recently achieved significant late-stage trial success for its experimental kidney disease drug, paving the way for accelerated regulatory approval. This breakthrough spotlights a broader investment opportunity in biopharmaceutical companies and medical researchers developing innovative treatments for chronic renal conditions.
Published: 10 March 2026
Explore BasketPenny Stocks to Watch
Looking for the next big thing at a small price? This carefully selected group of stocks under $5 has caught the attention of professional hedge funds. These hidden gems might offer significant growth potential for investors willing to take on some risk.
Published: 27 May 2025
Explore BasketWhy You’ll Want to Watch This Stock
Niche filtration demand
Products target clinical and water-purification niches where quality matters; growth depends on adoption and reimbursement, though performance can vary.
Regulatory and market access
Regulatory approvals and contractual access to hospitals or municipalities are key growth drivers; setbacks or delays can affect prospects.
Small-cap dynamics
With a modest market cap, the stock can swing widely and may have limited liquidity, so consider risk tolerance and diversify accordingly.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
